Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Melanoma and Skin Cancer

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

Melanoma Res.

Dudda M, Mann C, Heinz J, Schmidgen I, Weid F, Kühn M, Saloga J, Grabbe S, Loquai C

doi: 10.1097/CMR.0000000000000703.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin Cancer

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Melanoma Res.

Hanna DL, Law SJ, Merrick SA, Heptinstall L, Bass P, Dupont P, Sheri A

doi: 10.1097/CMR.0000000000000651.

Melanoma and Skin Cancer

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature

J Immunother.

Anastasopoulou A, Papaxoinis G, Diamantopoulos P, Christofidou E, Benopoulou O, Stratigos A, Gogas H

Melanoma and Skin Cancer

Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature

Melanoma Res.

Zafar FS, Richey P, Okereke U, Milhem M, Abid R, Powers JG, Swick B

doi: 10.1097/CMR.0000000000000713.Visit the original publication at ncbi.nlm.nih.gov

Hypersensitivity

[Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors]

Ann Dermatol Venereol.

Rohmer E, Scrivener JN, Schissler C, Cribier B, Lenormand C

doi: 10.1016/j.annder.2019.08.012.

Immunotherapy

A severe case of neuro-Sjögren's syndrome induced by pembrolizumab

J Immunother Cancer.

Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M

doi: 10.1186/s40425-018-0429-4.

Melanoma and Skin Cancer

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

Br J Dermatol.

Gault A, Anderson AE, Plummer R, Stewart C, Pratt AG, Rajan N

doi: 10.1111/bjd.19750.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin Cancer

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

BMC Cancer.

Ozaki Y, Shindoh J, Miura Y, Nakajima H, Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, Tanaka T, Haruta S, Ueno M, Kitano S, Fujii T, Udagawa H, Takano T

doi: 10.1186/s12885-017-3785-4.

Melanoma and Skin CancerImmunotherapy

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review

Neuromuscul Disord.

Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA

doi: 10.1016/j.nmd.2017.01.002.

Related content

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature

Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature

[Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors]

A severe case of neuro-Sjögren's syndrome induced by pembrolizumab

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review